Literature DB >> 16335904

Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and non-depressed euglycemic women of reproductive age.

Robert P Kauffman1, V Daniel Castracane, Debie L White, Sandra D Baldock, Ron Owens.   

Abstract

INTRODUCTION: Major depression in women of reproductive age may be accompanied by multiple endocrine and metabolic disturbances, which, in turn, may affect reproductive functioning. Enhanced cortisol synthesis, impaired leptin production and diminished insulin sensitivity have been reported in some depressed populations. We sought to determine whether an 8-week administration of citalopram would have an effect on these endocrine factors in a group of euglycemic depressed and non-depressed women of reproductive age.
MATERIALS AND METHODS: Fourteen depressed and 18 non-depressed women (diagnosed by structured clinical interview) aged between 18 and 45 years completed an 8-week study. All depressed women were treated with citalopram and non-depressed subjects randomized to citalopram or no treatment in an open label cohort study. An oral glucose tolerance test with insulin levels was performed at baseline and at the end of the 8-week trial. Weight, blood pressure, fasting serum cortisol, fasting serum leptin and Beck Depression Inventory were assessed at baseline, 2, 4 and 8 weeks.
RESULTS: Citalopram significantly improved depressive symptoms and Beck Depression Inventory scores in the depressed cohort. Cortisol production was higher in depressed women but did not diminish with citalopram therapy over 8 weeks. Indices of insulin sensitivity and leptin production were similar between depressed and non-depressed women and did not change despite citalopram therapy.
CONCLUSION: . Insulin sensitivity in moderately depressed women of reproductive age does not differ from that in a similar group of non-depressed women. Insulin sensitivity, cortisol secretion and leptin production do not change significantly in depressed women following an 8-week course of citalopram despite substantial improvement in depression scores.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16335904     DOI: 10.1080/09513590500216800

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  14 in total

Review 1.  The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications.

Authors:  Roger S McIntyre; Ka Young Park; Candy W Y Law; Farah Sultan; Amanda Adams; Maria Teresa Lourenco; Aaron K S Lo; Joanna K Soczynska; Hanna Woldeyohannes; Mohammad Alsuwaidan; Jinju Yoon; Sidney H Kennedy
Journal:  CNS Drugs       Date:  2010-09       Impact factor: 5.749

2.  Leptin levels are associated with decreased depressive symptoms in women across the weight spectrum, independent of body fat.

Authors:  Elizabeth A Lawson; Karen K Miller; Justine I Blum; Erinne Meenaghan; Madhusmita Misra; Kamryn T Eddy; David B Herzog; Anne Klibanski
Journal:  Clin Endocrinol (Oxf)       Date:  2012-04       Impact factor: 3.478

Review 3.  A review of the association between depression and insulin resistance: pitfalls of secondary analyses or a promising new approach to prevention of type 2 diabetes?

Authors:  Naomi Silva; Evan Atlantis; Khalida Ismail
Journal:  Curr Psychiatry Rep       Date:  2012-02       Impact factor: 5.285

Review 4.  [Depression and diabetes mellitus type 2].

Authors:  M Deuschle; U Schweiger
Journal:  Nervenarzt       Date:  2012-11       Impact factor: 1.214

Review 5.  [Depression and epilepsy : Two clinical pictures with common causes?].

Authors:  M Borgmann; M Holtkamp; M Adli; J Behr
Journal:  Nervenarzt       Date:  2016-07       Impact factor: 1.214

6.  Serum brain-derived neurotrophic factor, vascular endothelial growth factor and leptin levels in patients with a diagnosis of severe major depressive disorder with melancholic features.

Authors:  Zeynep Kotan; Emre Sarandöl; Emine Kırhan; Güven Ozkaya; Selcçuk Kırlı
Journal:  Ther Adv Psychopharmacol       Date:  2012-04

7.  Depression, depression treatment, and insulin sensitivity in adults at risk for type 2 diabetes.

Authors:  Julie Wagner; Nancy A Allen; Leah M Swalley; Gail D Melkus; Robin Whittemore
Journal:  Diabetes Res Clin Pract       Date:  2009-08-31       Impact factor: 5.602

8.  Treatment with an SSRI antidepressant restores hippocampo-hypothalamic corticosteroid feedback and reverses insulin resistance in low-birth-weight rats.

Authors:  Esben S Buhl; Thomas Korgaard Jensen; Niels Jessen; Betina Elfving; Christian S Buhl; Steen B Kristiansen; Rasmus Pold; Lasse Solskov; Ole Schmitz; Gregers Wegener; Sten Lund; Kitt Falck Petersen
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-01-26       Impact factor: 4.310

9.  Different Endocrine Effects of an Evening Dose of Amitriptyline, Escitalopram, and Placebo in Healthy Participants.

Authors:  Lukas Frase; John Peter Doerr; Bernd Feige; Maria Rechenbach; Bernd L Fiebich; Dieter Riemann; Christoph Nissen; Ulrich Voderholzer
Journal:  Clin Psychopharmacol Neurosci       Date:  2018-08-31       Impact factor: 2.582

Review 10.  A systematic review and meta-analysis of the association between depression and insulin resistance.

Authors:  Carol Kan; Naomi Silva; Sherita Hill Golden; Ulla Rajala; Markku Timonen; Daniel Stahl; Khalida Ismail
Journal:  Diabetes Care       Date:  2013-02       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.